We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Albumin-Bound Paclitaxel: In Metastatic Breast Cancer.
- Authors
Robinson, Dean M.; Keating, Gillian M.
- Abstract
▴ A new formulation of paclitaxel, 130-nanometre albumin-bound paclitaxel (nab-paclitaxel), solubilises hydrophobic paclitaxel and may increase paclitaxel delivery to tumour cells.▴ Intravenous nab-paclitaxel 260 mg/m had a higher maximum whole-blood concentration, shorter time to peak concentration, larger distribution volume and greater clearance than a 175 mg/m dose of a conventional polyoxyethylated castor oil (Cremophor EL) solublised paclitaxel (CrEL-paclitaxel).▴ The reconciled target-lesion response rate was significantly higher in patients receiving intravenous nab-paclitaxel 260 mg/m once every 3 weeks than in those receiving CrEL-paclitaxel 175 mg/m once every 3 weeks (21.5% vs 11.1%) in a randomised, nonblind, phase III trial in 454 patients with metastatic breast cancer.▴ The objective response rate (ORR) was also significantly greater in nab-paclitaxel than in CrEL-paclitaxel recipients (33% vs 19%).▴ In noncomparative phase II trials, ORRs of 48% and 51% were observed in patients receiving nab-paclitaxel 175 or 300 mg/m once every 3 weeks.▴ nab-Paclitaxel 260 mg/m caused less grade 4 neutropenia than CrEL-paclitaxel 175 mg/m. The incidence of grade 3 sensory neuropathy was higher in nab-paclitaxel recipients, reflecting the higher dosage of nab-paclitaxel, and improved with treatment interruption. Despite the absence of corticosteroid and antihistamine premedication, no severe hypersensitivity reactions were reported.(Table is included in full-text article.)
- Subjects
PACLITAXEL; ALKALOIDS; ANTINEOPLASTIC agents; MICROBIAL metabolites; CASTOR oil; TUMORS; BREAST cancer; ADRENOCORTICAL hormones; ANTIHISTAMINES; PREANESTHETIC medication
- Publication
Drugs, 2006, Vol 66, Issue 7, p941
- ISSN
0012-6667
- Publication type
Article
- DOI
10.2165/00003495-200666070-00007